The use of liposomes as carriers of lipophilic anthracycline antibiotics

Roman Perez-Soler, Yiyu Zou, Yi He Ling, Waldemar Priebe

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Tumor drug resistance and lack of tumor selectivity are the two main limitations of current systemic anticancer therapy. Liposomes have been shown to decrease certain doxorubicin (Dox)-related toxicities. By modifying liposome size and composition, the tumor localization of liposome entrapped drugs can be greatly enhanced. Through extensive structure-activity studies aimed at identifying anthracycline antibiotics which combine an enhanced affinity for lipid membranes and an ability to overcome multidrug resistance (MDR), we have identified Annamycin (Ann), which is ideally suited for entrapment in liposomes of different size and composition and has shown remarkable in vivo antitumor activity in different tumor models that display natural or acquired resistance to Dox. The unprecedented liposome formulation flexibility offered by Ann is expected to facilitate current efforts aimed at developing pharmaceutically acceptable liposomal-Ann formulations with optimal tumor targeting properties.

Original languageEnglish (US)
Pages (from-to)555-573
Number of pages19
JournalJournal of Liposome Research
Volume4
Issue number1
DOIs
StatePublished - 1994
Externally publishedYes

Fingerprint

Anthracyclines
Liposomes
Anti-Bacterial Agents
Neoplasms
Doxorubicin
Multiple Drug Resistance
Membrane Lipids
Drug Resistance
Pharmaceutical Preparations
annamycin

ASJC Scopus subject areas

  • Pharmaceutical Science
  • Pharmacology

Cite this

The use of liposomes as carriers of lipophilic anthracycline antibiotics. / Perez-Soler, Roman; Zou, Yiyu; Ling, Yi He; Priebe, Waldemar.

In: Journal of Liposome Research, Vol. 4, No. 1, 1994, p. 555-573.

Research output: Contribution to journalArticle

@article{edbe5a4e51324d13b46c61d5a28b83da,
title = "The use of liposomes as carriers of lipophilic anthracycline antibiotics",
abstract = "Tumor drug resistance and lack of tumor selectivity are the two main limitations of current systemic anticancer therapy. Liposomes have been shown to decrease certain doxorubicin (Dox)-related toxicities. By modifying liposome size and composition, the tumor localization of liposome entrapped drugs can be greatly enhanced. Through extensive structure-activity studies aimed at identifying anthracycline antibiotics which combine an enhanced affinity for lipid membranes and an ability to overcome multidrug resistance (MDR), we have identified Annamycin (Ann), which is ideally suited for entrapment in liposomes of different size and composition and has shown remarkable in vivo antitumor activity in different tumor models that display natural or acquired resistance to Dox. The unprecedented liposome formulation flexibility offered by Ann is expected to facilitate current efforts aimed at developing pharmaceutically acceptable liposomal-Ann formulations with optimal tumor targeting properties.",
author = "Roman Perez-Soler and Yiyu Zou and Ling, {Yi He} and Waldemar Priebe",
year = "1994",
doi = "10.3109/08982109409037061",
language = "English (US)",
volume = "4",
pages = "555--573",
journal = "Journal of Liposome Research",
issn = "0898-2104",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - The use of liposomes as carriers of lipophilic anthracycline antibiotics

AU - Perez-Soler, Roman

AU - Zou, Yiyu

AU - Ling, Yi He

AU - Priebe, Waldemar

PY - 1994

Y1 - 1994

N2 - Tumor drug resistance and lack of tumor selectivity are the two main limitations of current systemic anticancer therapy. Liposomes have been shown to decrease certain doxorubicin (Dox)-related toxicities. By modifying liposome size and composition, the tumor localization of liposome entrapped drugs can be greatly enhanced. Through extensive structure-activity studies aimed at identifying anthracycline antibiotics which combine an enhanced affinity for lipid membranes and an ability to overcome multidrug resistance (MDR), we have identified Annamycin (Ann), which is ideally suited for entrapment in liposomes of different size and composition and has shown remarkable in vivo antitumor activity in different tumor models that display natural or acquired resistance to Dox. The unprecedented liposome formulation flexibility offered by Ann is expected to facilitate current efforts aimed at developing pharmaceutically acceptable liposomal-Ann formulations with optimal tumor targeting properties.

AB - Tumor drug resistance and lack of tumor selectivity are the two main limitations of current systemic anticancer therapy. Liposomes have been shown to decrease certain doxorubicin (Dox)-related toxicities. By modifying liposome size and composition, the tumor localization of liposome entrapped drugs can be greatly enhanced. Through extensive structure-activity studies aimed at identifying anthracycline antibiotics which combine an enhanced affinity for lipid membranes and an ability to overcome multidrug resistance (MDR), we have identified Annamycin (Ann), which is ideally suited for entrapment in liposomes of different size and composition and has shown remarkable in vivo antitumor activity in different tumor models that display natural or acquired resistance to Dox. The unprecedented liposome formulation flexibility offered by Ann is expected to facilitate current efforts aimed at developing pharmaceutically acceptable liposomal-Ann formulations with optimal tumor targeting properties.

UR - http://www.scopus.com/inward/record.url?scp=0028288225&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028288225&partnerID=8YFLogxK

U2 - 10.3109/08982109409037061

DO - 10.3109/08982109409037061

M3 - Article

VL - 4

SP - 555

EP - 573

JO - Journal of Liposome Research

JF - Journal of Liposome Research

SN - 0898-2104

IS - 1

ER -